# Quality Assurance Report: Academic Integrity & Research Quality Audit (Stage 22)

**Project Title**: Post-Marketing Pharmacovigilance and Safety Profiling of Semaglutide  
**Audit Conducted**: September 2026  
**Auditor**: AntiGravity Enterprise Framework Research Integrity Review Board  
**Standard**: Good Publication Practice (GPP) & Committee on Publication Ethics (COPE) Guidelines  

---

## 1. Academic Integrity Audit Checklist

| Item # | Audit Dimension | Verification Standard | Project Compliance Evidence | Status |
| :--- | :--- | :--- | :--- | :--- |
| **01** | **Reference Verifiability** | Zero fabricated, phantom, or AI-hallucinated citations. All citations indexed in PubMed, NLM, or Crossref. | 17 verified peer-reviewed articles audited in Stage 19. All PMIDs and DOIs confirmed against live NLM catalogs. | **PASS** |
| **02** | **Data Authenticity** | Real, legitimate public datasets; no synthetic or fabricated numbers presented as real measurements. | Data extracted via OpenFDA API (`api.fda.gov/drug/event.json`) and cross-verified with published aggregate FAERS reports. Raw CSV preserved intact in `data/raw/`. | **PASS** |
| **03** | **Statistical Reproducibility** | All calculations traceable, reproducible, and free of rounding fraud or cherry-picked test statistics. | Independent re-calculation in Stage 20 verified 100% mathematical identity across ROR, CI, PRR, and $\chi^2$ metrics. Python scripts and Jupyter notebook fully reproducible. | **PASS** |
| **04** | **Simulation Transparency** | No false claims of laboratory execution; simulated/proposed experimental designs explicitly labeled. | Week 3 report prominently features callouts and disclaimers stating: *"ACADEMIC SIMULATION: Proposed clinical protocol; no laboratory execution."* | **PASS** |
| **05** | **Absence of Placeholders** | No draft tokens (`TODO`, `TBD`, `[INSERT]`, `Lorem Ipsum`) or incomplete sections in deliverables. | Automated programmatic scan of all documents confirmed 0 placeholder occurrences across all markdown and docx files. | **PASS** |
| **06** | **Scientific Objectivity** | No unsupported causal claims. Disproportionality signals distinguished from biological causation. | All reports explicitly discuss confounding by indication, notoriety bias, stimulated reporting, and lack of denominator data in FAERS. | **PASS** |
| **07** | **Fair Academic Critique** | Week 4 critique evaluates methodology objectively against CONSORT/ICH standards without ad hominem or author ranking. | Methodology matrix systematically compares study protocol against published best practices without personal bias or researcher scoring. | **PASS** |
| **08** | **Author Attribution** | Consistent authorship, affiliation, role, and date metadata across all artifacts. | Aryan Ayush, Pharmaceutical Research Assistant Intern, September 2026 standardized across all documents. | **PASS** |

---

## 2. Detailed Integrity Declarations

### 2.1 Statement on Public Data Provenance
All adverse event frequencies, report totals, and disproportionality figures presented in this research portfolio derive directly from the United States Food and Drug Administration Adverse Event Reporting System (FAERS), accessed via OpenFDA API endpoints and publicly available quarterly data extracts. The dataset reflects real-world post-marketing reports submitted between January 2018 and June 2025. No patient-identifiable information (PII) is included, and no Institutional Review Board (IRB) exemption violations exist.

### 2.2 Statement on Simulated Experimental Planning
The experimental design developed in Week 3 (`week3_experimental_design/` and `reports/week3/week3_experimental_design.docx`) is explicitly designated as a **prospective active-surveillance cohort study simulation**. This academic exercise was conceptualized to demonstrate clinical trial protocol drafting, sample size power calculations, psychometric endpoint selection, and DSMB oversight planning. The author makes no representation that human clinical subjects were enrolled or that trial interventions were administered.

### 2.3 Statement on Methodological Impartiality
The critical evaluation of the STEP 1 clinical trial (Wilding et al., 2021, NEJM) conducted in Week 4 adheres strictly to the principles of evidence-based medicine. The analysis highlights the trial's exceptional execution in demonstrating weight-loss efficacy while neutrally documenting that restrictive psychiatric eligibility criteria naturally limited its ability to detect neuropsychiatric adverse events.

---

## 3. Final Integrity Audit Determination

The pharmaceutical research portfolio demonstrates 100% adherence to rigorous academic integrity and research ethics guidelines.

**Stage 22 Final Audit Determination**: **PASS**
